Scientific evidences about therapies for pyoderma gangrenosum: an integrative review
DOI:
https://doi.org/10.5205/1981-8963-v10i11a11502p4150-4156-2016Abstract
ABSTRACT
Objective: to analyze the scientific evidences about the therapies for pyoderma gangrenosum. Method: an integrative review, in the period from 2005 to 2015, in the Lilacs, Medline and SciELO library. The process was guided by the question: What are the scientific evidences about the current treatment for Pyoderma Gangrenosum? The data analysis was performed in a descriptive way. Results: the evidences were synthesized from the corpus of study, consisting of 15 primary studies. All studies were case studies and addressed the therapy from two perspectives: topical and systemic. Conclusion: it is recommended that the association between both topical therapies and systemic, which include the use of corticosteroids, rifampicin, infliximab, hyperbaric oxygen therapy and occlusive dressings with covers of thin foam or hydrocolloid. Descriptors: Pyoderma Gangrenosum; Therapeutic; Clinical Practice Based on Evidences.
RESUMO
Objetivo: analisar as evidências científicas acerca das terapêuticas para o Pioderma Gangrenoso. Método: revisão integrativa, no período de 2005 a 2015, nas bases de dados Lilacs, Medline e na biblioteca SciELO. O processo foi norteado pela pergunta: Quais as evidências científicas acerca das terapêuticas atuais para o Pioderma Gangrenoso? A análise dos dados foi realizada de forma descritiva. Resultados: as evidências foram sintetizadas do corpus do estudo, composto por 15 estudos primários. Todos os estudos analisados eram estudos de caso e abordavam a terapêutica sob duas perspectivas: tópica e sistêmica. Conclusão: recomenda-se a associação entre ambas as terapias tópicas e sistêmicas, que incluem o uso de corticoides, rifampicina, infliximab, oxigenoterapia hiperbárica e curativos oclusivos com coberturas de espuma fina ou hidrocolóide. Descritores: Pioderma Gangrenoso; Terapêutica; Prática Clínica Baseada em Evidências.
RESUMEN
Objetivo: analizar las evidencias científicas acerca de los tratamientos para el pioderma gangrenoso. Método: esta es una revisión integradora, en el período de 2005 a 2015, en el MEDLINE y LILACS, SciELO biblioteca. El proceso fue guiado por la pregunta: ¿Cuáles son las pruebas científicas acerca del tratamiento actual para el pioderma gangrenoso? El análisis de los datos se realizó de manera descriptiva. Resultados: las evidencias fueron sintetizadas a partir del corpus de estudio consta de 15 estudios primarios. Todos los estudios fueron estudios de casos y la terapia dirigida desde dos perspectivas: tópica y sistémica. Conclusión: Se recomienda que la asociación entre ambos tratamientos tópicos y sistémicos, que incluyen el uso de corticosteroides, rifampicina, infliximab, oxigenoterapia hiperbárica y vendajes oclusivos con cubiertas de fina espuma o hidrocoloide. Descriptores: Pioderma Gangrenoso; Medicamentos; La Práctica Clínica Basada en la Evidencia.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Journal of Nursing UFPE on line

This work is licensed under a Creative Commons Attribution 4.0 International License.
Since 2025, authors retain the copyright to their works and grant the Revista de Enfermagem UFPE on line – REUOL the right of first publication, with the work simultaneously licensed under the Creative Commons Attribution 4.0 International license (CC BY 4.0). The Revista de Enfermagem UFPE on line – REUOL retains the copyright to works published in issues from 2007 to 2024 and grants the Creative Commons Attribution 4.0 International license (CC BY 4.0) to this content in order to ensure Open Access.
Any user has the right to:
Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you comply with the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.



















